1562993-37-6

1562993-37-6 structure

Name: Ponatinib-d8
Chemical Name: Ponatinib D8
CAS Number: 1562993-37-6
Molecular Formula: C₂₉H₁₉D₈F₃N₆O
Molecular Weight: 540.60900
Catalog: Signaling Pathways Autophagy Autophagy
Create Date: 2018-07-05 08:03:32
Modify Date: 2026-07-01 18:10:22
Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

Name	Ponatinib D8
Synonyms	AP24534 D8 [2H8]-Ponatinib 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((2,2,3,3,5,5,6,6-octadeutero-4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide D8-Ponatinib Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl-2,2,3,3,5,5,6,6-d8)methyl]-3-(trifluoromethyl)phenyl]

Description	Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PDGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Src Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FGFR Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR
Target	c-Kit:12.5 nM (IC50) VEGFR2:1.5 nM (IC50) FGFR1:2.2 nM (IC50) PDGFRα:1.1 nM (IC50)
References	[1]. O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.